Our passion is to improve treatments for diseases. We are developing the next generation of bio-pharmaceuticals using molecular shields that increase the bio-availability of therapeutics in circulation with focus on oral delivery, autoimmune diseases and excessive inflammation. The aim is to reduce risks and costs associated with disease management. Our technology and molecules have applications in the areas of autoimmune diseases, vaccines (DNA, RNA and subunit), gene therapy, neuroscience and oncology.
To develop novel therapeutics for the treatment of diseases.
Cell Reserves Inc. is developing a molecular shield technology to increase the bio-availability of bio-therapeutics in the circulation. It is simpler, modular and practical. This platform offers prospects for oral delivery and reducing dosing frequency, dose sizes and side effects. It also offers faster penetration of therapeutics into difficult to reach areas that are not readily accessible including solid tumors and tissues.
Our current focus is developing treatments for autoimmune diseases including myasthenia gravis, pemphigus, thyroid eye disease and related Graves’ disease, warm autoimmune hemolytic anemia, immune thrombocytopenia purpura, lupus, arthritis and various other related inflammatory immune conditions. We have identified proprietary ligand(s) that inhibit an important regulatory receptor involved in these diseases and conditions. The prediction is that our ligand(s) offer more precise and safer alternative than broadly acting known agents.
We are interested in strategic alliances to co-develop therapeutics for human and veterinary needs.
For co-developing therapeutics, joint ventures and our molecular technologies or collaborations concerning our pipeline, please contact us by emailing firstname.lastname@example.org